Expanded Treatment Protocol in Acute Lymphoblastic Leukemia

Official Title

Expanded Treatment Protocol for Relapsed/Refractory Pediatric/Young Adult Acute Lymphoblastic Leukemia Patients to be Treated With CTL019

Summary:

This is a single arm, open-label, multi-centre, phase II study to determine the safety and efficacy of CTL019 in pediatric/young adult patients with r/r B-cell ALL.

Trial Description

This is a single arm, open-label, multi-centre, phase II study to determine the safety and efficacy of CTL019 in pediatric/young adult patients with r/r B-cell ALL. The study will have the following sequential phases: Screening, Pre-Treatment (Cell Product Preparation & Lymphodepleting Chemotherapy), Treatment and Follow-up. The total duration of the study is 1 year from CTL019 cell infusion.

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.

Resources

Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society